Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma
Published in: TISSUE ANTIGENS
Access to document
10.1111/j.1399-0039.2008.01005.x
Classical Hodgkin’s lymphoma (cHL) is characterized by the presence of an abundant reactive infiltrate, lacking effective cytotoxic responses. Especially in Epstein-Barr virus (EBV)-negative cHL, the neoplastic Hodgkin-Reed-Sternberg (HRS) cells have lost protein expression of major histocompatibility complex (MHC) class I, enabling escape from cytotoxic T lymphocyte (CTL) responses. However, downregulation of MHC class I generally induces natural killer (NK) cell activation. The paucity of NK cells in the reactive infiltrate of cHL and the systemic NK cell deficiency observed in cHL patients led us to investigate the expression...
Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22
Published in: British Journal of Haematology
Access to document
10.1111/j.1365-2141.2007.06964.x
Hodgkin lymphoma (HL) is characterized by a minority of neoplastic Hodgkin-Reed Sternberg (HRS) cells surrounded by a non-neoplastic reactive infiltrate. As immunological mechanisms appear to be crucial in classical HL pathogenesis, altered serum chemokine levels might be related to disease activity. Serum levels of nine chemokines were examined in 163 untreated HL patients and 334 controls. We investigated single nucleotide polymorphisms (SNPs) for association with serum CCL17 (thymus and activation-regulated chemokine, TARC) levels and HL susceptibility. Serum CCL17 and CCL22 (macrophage-derived chemokine, MDC) levels were significantly increased in...
Marijke Niens, Lydia Visser, I.M Nolte, Gerrit van der Steege, Arjan Diepstra, P. Cordano, R.F. Jarrett, G.J. te Meerman, Sibrand Poppema, Anke van den Berg
Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes
Published in: Blood
Access to document
10.1182/blood-2007-09-112128
Hodgkin and Reed-Sternberg (HRS) cells in Hodgkin lymphoma (HL) secrete factors that interact with inflammatory background cells and may serve as biomarkers for disease activity. To detect new proteins related to pathogenesis, we analyzed the secretome of HRS cells. Proteins in cell culture supernatant of 4 HL cell lines were identified using 1 DGE followed by in-gel trypsin digestion and LC-MS/MS. In total, 1290 proteins, including 368 secreted proteins, were identified. Functional grouping of secreted proteins revealed 37 proteins involved in immune response. Sixteen of the 37 proteins...
Yue Ma, Lydia Visser, Johan Roelofsen, Marcel de Vries, Arjan Diepstra, Gustaaf van Imhoff, Tineke van der Wal, Marjan Luinge, Gloria Alvarez Llamas, Hans Vos, Sibrand Poppema, Roel Vonk, Anke van den Berg
Autoimmune lymphoproliferative syndrome in a patient with a new minimal deletion in the death domain of the FAS gene
Published in: Human Pathology
Access to document
10.1016/j.humpath.2007.07.013
We present a case of autoimmune lymphoproliferative syndrome (ALPS) caused by a previously undescribed minimal deletion in the death domain of the FAS gene. ALPS is an uncommon disease associated with an impaired Fas-mediated apoptosis. The patient presented with a history of splenomegaly since 4 months of age, associated with cervical lymphadenopathy, which improved with oral corticosteroid treatment. Relevant laboratory findings were the presence of anemia, thrombocytopenia, and positive direct and indirect Coombs tests. He was not an offspring of consanguineous parents. Two cervical lymph node biopsies were...
Gabrieta Gualco, Anke van den Berg, Sicco Koopmans, Livia M. Bacchi, Siderley S. Carneiro, Everaldo Ruiz, Ana Paula Vecchi, John K. C. Chan
HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBVI Hodgkin lymphoma
Published in: Blood
Access to document
10.1182/blood-2007-05-086934
Previous studies showed that the HLA class I region is associated with Epstein-Barr virus (EBV)-positive Hodgkin lymphoma (HL) and that HLA-A is the most likely candidate gene in this region. This suggests that antigenic presentation of EBV-derived peptides in the context of HLA-A is involved in the pathogenesis of EBV+ HL by precluding efficient immune responses. We genotyped exons 2 and 3, encoding the peptide-binding groove of HLA-A, for 32 single nucleotide polymorphisms in 70 patients with EBV+ HL, 31 patients with EBV- HL, and 59 control participants....
Marijke Niens, Ruth F. Jarreft, Bouke Hepkema, Ilja M. Nolte, Arjan Diepstra, Mathieu Platteel, Niels Kouprie, Craig P. Delury, Alice Gallagher, Lydia Visser, Sibrand Poppema, Gerard J. te Meerman, Anke Van den Berg